Your email has been successfully added to our mailing list.

×
0 0 0 0 -0.000395256916996109 0 0 0.015810276679842
Stock impact report

TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1 First-in-Human Trial of Umbralisib in The Lancet Oncology

TG Therapeutics, Inc. (TGTX) 
Last tg therapeutics, inc. earnings: 11/12 07:34 am Check Earnings Report
US:NASDAQ Investor Relations: ir.tgtherapeutics.com
Company Research Source: GlobeNewswire
Umbralisib is structurally distinct from other PI3K delta inhibitors with greater selectivity to PI3K delta and unique complementary inhibition of casein kinase-1 (CK1) epsilon Single agent umbralisib was well tolerated, with limited Adverse Events (AEs) commonly associated with other PI3K delta inhibitors NEW YORK, Feb. 21, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) announced the publication of the results from the Phase 1 first-in-human study of umbralisib (TGR-1202), the Company's novel once-daily PI3K delta inhibitor, in The Lancet Oncology.  The paper includes safety and efficacy information from 90 patients with relapsed or refractory b-cell malignancies, including patients with Chronic Lymphocytic Leukemia (CLL) and various forms of lymphoma treated with single agent umbralisib.  In this study, umbralisib was well tolerated with a favorable safety profile distinct from prior generation PI3K delta inhibitors.  Grade 3/4 immune mediated AEs commonly associat Show less Read more
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
TGTX alerts

from News Quantified
Opt-in for
TGTX alerts

from News Quantified